CoChat

Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy

Open access
Yanagita, Tadahiko, Murata, Yoji, Tanaka, Daisuke, Motegi, Sei-ichiro, Arai, Eri, Daniwijaya, Edwin Widyanto, Hazama, Daisuke, Washio, Ken, Saito, Yasuyuki, Kotani, Takenori, Ohnishi, Hiroshi, Oldenborg, Per-Arne, Garcia, Noel Verjan, Miyasaka, Masayuki, Ishikawa, Osamu, Kanai, Yae, Komori, Takahide, Matozaki, Takashi · 2017 · JCI Insight
Cited by 153

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Tumor cells are thought to evade immune surveillance through interaction with immune cells. Much recent attention has focused on the modification of immune responses as a basis for new cancer treatments. SIRPα is an Ig superfamily protein that inhibits phagocytosis in macrophages upon interaction with its ligand CD47 expressed on the surface of target cells. Here, we show that SIRPα is highly expressed in human renal cell carcinoma and melanoma. Furthermore, an anti-SIRPα Ab that blocks the interaction with CD47 markedly suppressed tumor formation by renal cell carcinoma or melanoma cells in immunocompetent syngeneic mice. This inhibitory effect of the Ab appeared to be mediated by dual mechanisms: direct induction of Ab-dependent cellular phagocytosis of tumor cells by macrophages and blockade of CD47-SIRPα signaling that negatively regulates such phagocytosis. The antitumor effect of the Ab was greatly attenuated by selective depletion not only of macrophages but also of NK cells or CD8 + T cells. In addition, the anti-SIRPα Ab also enhances the inhibitory effects of Abs against CD20 and programmed cell death 1 (PD-1) on tumor formation in mice injected with SIRPα-nonexpressing tumor cells. Anti-SIRPα Abs thus warrant further study as a potential new therapy for a broad range of cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci.insight.89140

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 153

Metadata

Authors
Yanagita, T., Murata, Y., Tanaka, D., Motegi, S.-I., Arai, E., Daniwijaya, E. W., Hazama, D., Washio, K., Saito, Y., Kotani, T., Ohnishi, H., Oldenborg, P.-A., Garcia, N. V., Miyasaka, M., Ishikawa, O., Kanai, Y., Komori, T., & Matozaki, T.
Venue
JCI Insight
Published
2017-01-12
Volume
2
Issue
1
Pages
e89140-e89140
ISSN
2379-3708 (ISSN-L)
OpenAlex
W2579381410
Cited by
153
References
9
FWCI
6.07
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy. https://app.cochat.ai/papers/10.1172/jci.insight.89140
The paper
Yanagita, T., Murata, Y., Tanaka, D., Motegi, S.-I., Arai, E., Daniwijaya, E. W., Hazama, D., Washio, K., Saito, Y., Kotani, T., Ohnishi, H., Oldenborg, P.-A., Garcia, N. V., Miyasaka, M., Ishikawa, O., Kanai, Y., Komori, T., & Matozaki, T. (2017). Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy. JCI Insight. https://doi.org/10.1172/jci.insight.89140

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.